PIH24 Intra Muscular Testosterone Undecanoate (TU) (NEBIDO®) as Testosterone Replacement Therapy (TRT) for Androgen Deficiency in the Aging Male (ADAM) and Diabetes Mellitus Type 2 (DM2) Patients: Brazilian Economic Modeling  by Silva, A.P. et al.
guanfacine extended release (GXR), to long-acting psychostimulants vs. maintain-
ing existing long-acting psychostimulant monotherapy in children and adoles-
cents with ADHD and suboptimal response to psychostimulant monotherapy.
METHODS: A one-year Markov model was developed from a US third-party payer
perspective. Effectiveness was measured by quality-adjusted life year (QALY). The
model assumed patients transitioned among four health states (normal, mild,
moderate, and severe), defined based on the Clinical Global Impressions-Severity
(CGI-S) scale. Transition probabilities were estimated in an ordered logit model
using patient-level data from a Phase III clinical trial comparing psychostimulants
plus GXR with psychostimulants plus placebo (n461). The model assumed that
patients in moderate or severe states after week eight would discontinue ADHD
treatment and remain in that state. Direct costs included drug wholesale acquisi-
tion costs (WAC) and medical costs, in 2010 US dollars. Health state utilities were
obtained from the literature. Disutilities associated with adverse events were ap-
plied for the first four weeks. One-way sensitivity analyses (SA) were conducted by
varying key model inputs. RESULTS: Adding GXR to existing psychostimulant
monotherapy was associated with an incremental drug cost of $1016 but lower
medical cost of $124, resulting in a total one-year incremental cost of $892. The
addition of GXR led to an incremental QALY of 0.03 and an incremental cost-
effectiveness ratio (ICER) of $31,660/QALY. In one-way SA, ICERs ranged from
$19,723/QALY to $46,631/QALY. CONCLUSIONS: This is the first cost-effectiveness
analysis of psychostimulants with adjunctive medication. Adjunctive therapy of
GXR with psychostimulants is cost-effective based on a willingness-to-pay thresh-
old of $50,000/QALY.
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OBJECTIVES: To determine the cost-effectiveness of TRT with TU (NEBIDO®) com-
pared with placebo for patients with ADAM and DM2, from the Brazilian Private
Healthcare System perspective. METHODS: The study was a cost-effectiveness
analysis based on Markov modeling to estimate costs and consequences of treat-
ments. Epidemiological and efficacy data derived from a critical appraisal of the
scientific literature. Only direct medical costs were considered. If available, costs of
clinical events (CE) were obtained from burden of disease studies. If not, Brazilian
official guidelines were obtained to determine the resources used to treat the CE.
Drug, hospital daily admission rates, procedures and laboratory tests unit costs
were obtained from Brazilian official databases. Costs and benefits were dis-
counted at 5% yearly. Outcomes were expressed as CE avoided. Probability sensi-
tivity analysis (PSA) was conducted to assess model robustness. Life time horizon
was analyzed. RESULTS: The systematic review showed that although the absence
of studies directly evaluating the impact of TU on cardiovascular events, their
favorable influence on cardiovascular disease intermediate markers suggests that
TU may have clinically relevant effect in patients at risk, especially in patients with
metabolic syndrome and/or DM2. The analysis showed higher clinical benefits and
costs for TU. Considering 100 patients, 75.2 and 140.0 CE happen in TU and placebo
arms, respectively. The average time-horizon cost per patient was
R$34,120(€14,896) and R$23,489(€10,255) for TU and placebo, respectively, resulting
in an incremental cost-effectiveness ratio (ICER) of R$16,390/CE avoided (€7,155/CE
avoided). PSA demonstrated that in 83.2% of the simulations TU was more effective
with higher cost and in 16.8% of the simulations TU was dominant compared to
placebo. CONCLUSIONS: Our study demonstrated that TU have clinically relevant
effect in reducing CE being highly cost-effective for ADAM treatment in patients
with DM2 at willingness-to-pay beyond R$19,000/CE avoided (€8,296/CE avoided)
(Brazilian GDP per capita). PSA confirmed this determinist result.
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OBJECTIVES: To estimate values for cost and effectiveness that assess the long-
term efficiency of public health intervention to prevent and correct childhood
obesity. METHODS: A Markov model was developed that takes into account five
diseases strongly associated with obesity: Diabetes Mellitus Type 2, Heart Disease,
Breast Cancer, Colon Cancer and Stroke. Selection of disease was in base of high
rates of morbidity and mortality. In the model, we considered 2 main states: nor-
mal weight (BMI 30 kg/m2) and obese (BMI 30 kg/m2). From them, individuals
can transit to states which representing the 5 diseases and death. Individuals can
transit between normal weight and obese until they reach a certain age (30) when
they can transit to the rest of states. The time horizon was 70 years. A literature
review was performed in order to estimate parameters. The measure of effective-
ness was QALYs and a discount of 3% was applied to costs and utilities. A 2-way
probabilistic sensitivity analysis was made over 2 parameters which define the
intervention: relative risk and cost of intervention. Also, a multivariate and prob-
abilistic sensitivity analysis by 2nd order Monte Carlo (MC) simulations was per-
formed for all parameters. Finally, acceptability curves and the expected value of
perfect information were calculated. RESULTS: If the willingness to pay is € 30,000/
QALY, any intervention that exceeds 1% prevention/correction, incurring in cost
not exceeding € 2 per child and per year should be implemented, because the
probability of hitting the decision is over 90% and does not incur on any opportu-
nity cost. CONCLUSIONS: Long term efficient public health interventions, to pre-
vent/correct childhood obesity, are low cost (not exceeding € 5 per child per year)
due to the effectiveness of interventions, usually lower than 2% of prevention/
correction over non-intervention.
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OBJECTIVES: Dienogest (Visanne ®) is a progestin that has recently been approved
in Europe, Australia and Japan (not in Korea yet) for the treatment of endometriosis
at a dose of 2 mg orally per day. Dienogest provides potent progestogenic effects,
combined with moderate suppression of estrogen levels and has no significant
androgenic, mineralocorticoid, or glucocorticoid activity. The aim of this analysis is
to evaluate cost-effectiveness of dienogest, thereby assessing its eligibility for Na-
tional Health Insurance coverage. METHODS: We carried out a cost-effectiveness
analysis comparing dienogest to leuprolide acetate, a gonodotropin releasing hor-
mone agonist (GnRH-agonist), the current standard treatment for endometriosis
associated pain after laparoscopy. Patients requiring additional treatment because
of pain after laparoscopy were included in the analysis. A third-party-payer per-
spective was taken. The time horizon of analysis was one year. Response to treat-
ment, time horizon of analysis, recurrence rate following discontinuation of
GnRH-a and the incidence of adverse event were considered as major factors for
the decision tree model. An expert survey was conducted to investigate the treat-
ment pattern. Costs of endometriosis were also assessed. In the base case scenario
patients do not receive any sequential treatment after non response or pain recur-
rence. Sensitivity analysis was performed for major variables. RESULTS: At the
base case analysis, dienogest was dominant. Sensitivity analysis showed that the
result was robust for the most variables. Drug cost was the most influential factor
of all. CONCLUSIONS: Dienogest is a cost-effective and cost-saving alternative in
the Korea National Health Insurance context. However the analysis is covering only
one year and long-term clinical data is required to draw a solid conclusion.
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OBJECTIVES: To evaluate the projected health outcomes, costs, and cost-effective-
ness of universal mass vaccination (UMV) with Rotarix™ (GlaxoSmithKline) in Can-
ada compared with no vaccination. METHODS: An age-compartmental, determin-
istic, static Markov cohort model was developed to simulate the disease process of
acute diarrhea events caused by rotavirus infection up to the age of 5 years in
‘monthly’ time cycles, using Canadian demographic and epidemiology data. The
base-case analysis was performed to estimate the direct effects of a UMV program
with two doses of Rotarix™ at 2 and 4 months of age compared to no vaccination,
assuming 90% vaccination coverage. Costs and utilities were discounted at 3.5%.
The efficacy of Rotarix™ was based on published clinical trial results. Model out-
puts include clinical endpoints (deaths, hospitalizations, emergency department
(ED) visits and outpatient visits), and economic measures (net costs per case/death
prevented and quality-adjusted life year gained). Incremental cost-effectiveness
ratios (ICERs) were calculated from the healthcare system perspective, and produc-
tivity loss was reported separately. One-way sensitivity analysis was performed to
evaluate the robustness of the model to variations in the underlying input
parameters. RESULTS:Without vaccination, a Canadian birth cohort of 380,000 can
be expected to have 152,000 rotavirus diarrhea events, 9,000 hospitalizations,
20,849 ED visits, 2,812 nosocomial infections and 6 deaths over 5 years. The base
case results show that a UMV program with Rotarix™ could reduce these events by
69%, 81%, 68%, 76% and 79% respectively over 5 years. At $60 per dose plus $9
administrative fee, the cost per QALY gained over no vaccination is $28,653.
CONCLUSIONS:A UMV program with Rotarix™ is projected to substantially reduce
the health and economic burden of rotavirus infections, and is cost-effective rela-
tive to no vaccination in the Canadian health care system.
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OBJECTIVES: Evaluate the potential benefits of the 10-valent pneumococcal non-
typeable Haemophilus influenzae (NTHi) protein D-conjugated vaccine (PHiD-CV)
and the 13-valent conjugated pneumococcal vaccine (PCV-13) for Argentina.
METHODS: A cohort Markov model was used. The model simulated the impact of
pneumococcal and NTHi related diseases (Invasive Disease (ID), Community Ac-
quired Pneumonia (CAP), and Acute Otitis Media (AOM)) in an argentinean cohort
followed over lifetime. Argentine epidemiology, disease management, and costs
were included in the model. Base case includes conservative assumptions on the
rates of NTHi infections. A 21 vaccination schedule was assumed, with vaccine
coverage of 90% and 2 prices/dose scenarios a) PAHO Revolving Fund 2011 prices, or
b) price parity. Results of the quality adjusted life years gained (QALYs) and future
averted costs, using a 3.5% discount rate, using the health payer perspective, are
presented. RESULTS: The model estimated comparable results between vaccines
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